-
ChainGen Bio Raises RMB 45M in Angel Round for X-oligo Conjugates Development
•
ChainGen Bio, a Shanghai-based developer of X-oligo conjugates (XOCs), has reportedly raised RMB 45 million (USD 6.2 million) in an angel financing round co-led by Matrix Partners and Frees Fund. The proceeds will be used to advance pipeline research and development, patent layout, and company operations, including laboratory platform construction.…
-
Yibao Technology Secures Series A+ Funding to Expand Health Insurance Services
•
Yibao Technology Co., Ltd, a Shanghai-based service provider for city-level supplementary commercial insurance (“Huiminbao”) schemes, has reportedly raised an undisclosed amount in a Series A+ financing round. The round was led by China Resources Pharmaceutical Group Ltd, China Resources Medicine Commercial Holdings Ltd, and China Resources Sanjiu Medical & Pharmaceutical…
-
Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing for its drug candidate HSK16149, intended for the treatment of diabetic peripheral neuropathic pain (DPNP), has been accepted for review by the National Medical Products Administration (NMPA). HSK16149 is an in-house Category 1 drug being…
-
Cowell Health Partners with AstraZeneca to Enhance Cancer Care at CIIE
•
Cowell Health has announced a partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) at the 5th China International Import Expo (CIIE), aimed at enhancing precision whole disease course management services for cancer patients. The collaboration focuses on improving accessibility to novel cancer treatments and other health services, particularly for patients with…
-
Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance
•
China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical clearance from the National Medical Products Administration (NMPA) for its ACYW135 meningococcal polysaccharide conjugate vaccine. The vaccine is designed to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis of groups A, C, Y, and W135.…
-
Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced the enrollment of the first patients for its ZKY001 in a Phase II clinical study in transepithelial photorefractive keratectomy (TPRK). The study will enroll 120 patients across 10 centers. Additionally, a separate Phase II clinical…
-
Zhaoke Ophthalmology Licenses C&V Tech’s TONO-i Tonometer for Greater China
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced a licensing agreement with South Korea’s C&V Tech, a glaucoma device firm. The agreement grants Zhaoke exclusive rights for registration, import, promotion, distribution, marketing, and sales of C&V Tech’s TONO-i tonometer in Greater China. No…
-
Insilico Medicine Partners with Sanofi for AI-Driven Drug Discovery
•
Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced a multi-year, multi-target strategic research collaboration with French pharmaceutical major Sanofi. The partnership aims to leverage Insilico Medicine’s AI platform, Pharma.AI, to advance drug development candidates for up to six new targets. Collaboration DetailsUnder the…
-
Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE
•
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based Pfizer (NYSE: PFE), the Chinese Alliance for Rare Disease (CARD), China Social Assistance Foundation (CSAF), and Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor. The collaboration aims to…
-
Pfizer China Partners with Alibaba Health for Disease Education at CIIE
•
The 5th China International Import Expo (CIIE) saw US-based Pfizer’s China unit announce a partnership with China-based Alibaba Health Information Technology Ltd (HKG: 0241). The collaboration aims to explore an innovative disease education model, though no financial details were disclosed. Partnership ObjectivesThe partnership between Pfizer’s China unit and Alibaba Health…
-
Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500
•
China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at the 5th China International Import Expo (CIIE). The collaboration targets the central laboratory program, aiming to enhance clinical studies and drug development plans centered around TruSight Oncology 500 (TSO 500), a research-only pan-cancer detection assay.…
-
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
•
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA), announced at the 5th China International Import Expo (CIIE). The collaboration will focus on exploring heart failure due to special causes, particularly thyroxine protein amyloid cardiomyopathy (ATTR-CM), aiming to revamp diagnosis and treatment protocols in…
-
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
•
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA), announced at the 5th China International Import Expo (CIIE). The collaboration will focus on exploring heart failure due to special causes, particularly thyroxine protein amyloid cardiomyopathy (ATTR-CM), aiming to revamp diagnosis and treatment protocols in…
-
MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial
•
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in a Phase I clinical study in China for its MRX-8, a new drug against gram-negative drug-resistant bacteria. This marks a significant milestone in the development of MRX-8, which aims to address the growing challenge of…
-
Zhifei Bio Initiates Global Study for Omicron-Delta COVID-19 Vaccine in Uzbekistan
•
China-based Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd has announced the initiation of a global clinical study for its Omicron-Delta variant recombinant COVID-19 protein vaccine in Uzbekistan. This marks a significant step in the development of the second-generation vaccine, which targets the Omicron and Delta variants. Previous Clinical StudiesPreviously, Zhifei Bio chose…
-
Mainline Biosciences Raises RMB 100M in Series A Financing for Peptide Drugs
•
Mainline Biosciences, a polypeptide drug developer based in Zhongshan, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A financing round. The round was led by Fuho Capital, with participation from Techsnow Capital and Dingfu Investment. The proceeds will be used to construct the company’s…
-
Jiangsu Trausim Raises RMB 100M in Series A Financing for Dental Implants
•
China-based Jiangsu Trausim Medical Instrument Co., Ltd, a wholly-owned subsidiary of Fulong Holdings and focused on dental implants and surgical instruments, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A financing round. The round was led by Sunho Capital and MF Capital, with participation…
-
Cyramza Prescribed in China for Advanced Gastric Cancer
•
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai and Beijing Cancer Hospital, marking a new treatment option for second-line advanced gastric cancer patients in China. This milestone follows the drug’s market approval in March 2022 for treating second-line advanced metastatic gastric cancer in…
-
Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization
•
German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus’ development process by utilizing Merck’s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization…
-
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
•
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has obtained its 10th indication approval from China’s National Medical Products Administration (NMPA). The drug can now be used to treat early high-risk triple negative breast cancer (TNBC) with tumors expressing PD-L1 (CPS ≥ 20) in…
